Shanghai Model Organisms Center(SH:688265) Xin Lang Cai Jing·2025-10-30 03:02Core Insights - Nanmo Biological (688265.SH) reported a total operating revenue of 303 million yuan for Q3 2025, ranking 35th among disclosed peers [1] - The company's net profit attributable to shareholders was 26.76 million yuan, ranking 25th among disclosed peers [1] - Operating cash flow was 19.64 million yuan, ranking 29th among disclosed peers [1] Financial Metrics - The latest debt-to-asset ratio is 10.38% [3] - The latest gross profit margin is 52.87% [3] - The latest return on equity (ROE) is 1.57%, ranking 25th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.34 yuan [3] - The total asset turnover ratio is 0.16 times, ranking 35th among disclosed peers [3] - The inventory turnover ratio is 9.37 times [3] Shareholder Information - The number of shareholders is 6,687, with the top ten shareholders holding 58.58 million shares, accounting for 75.13% of the total share capital [3] - The top ten shareholders and their holdings are as follows: - Shanghai Dish Stone Enterprise Management Consulting Co., Ltd.: 35.6% - Shanghai Science and Technology Venture Capital Co., Ltd.: 13.81% - Suzhou Haiwang Hezhong No.1 Equity Investment Partnership (Limited Partnership): 11.1% - Shanghai Pudong New Industry Investment Co., Ltd.: 7.86% - Kangjun Investment Management (Beijing) Co., Ltd.: 2.00% - Zhang Kui: 2.00% - Qu Fabing: 1.01% - Shanghai Huashen Asset Management Co., Ltd.: 0.64% - Shanghai Puyu Enterprise Management Consulting Partnership (Limited Partnership): 0.58% - China Merchants Securities Co., Ltd.: 0.48% [3]